Compare LEA & PTCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LEA | PTCT |
|---|---|---|
| Founded | 1917 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4B | 5.3B |
| IPO Year | N/A | 2013 |
| Metric | LEA | PTCT |
|---|---|---|
| Price | $113.38 | $75.56 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 17 |
| Target Price | ★ $116.50 | $73.76 |
| AVG Volume (30 Days) | 688.9K | ★ 2.2M |
| Earning Date | 10-31-2025 | 11-04-2025 |
| Dividend Yield | ★ 2.71% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 8.17 | ★ 8.94 |
| Revenue | ★ $22,985,100,000.00 | $1,779,150,000.00 |
| Revenue This Year | N/A | $128.32 |
| Revenue Next Year | $1.81 | N/A |
| P/E Ratio | $13.91 | ★ $8.46 |
| Revenue Growth | N/A | ★ 97.54 |
| 52 Week Low | $73.85 | $35.95 |
| 52 Week High | $114.67 | $87.50 |
| Indicator | LEA | PTCT |
|---|---|---|
| Relative Strength Index (RSI) | 64.72 | 50.79 |
| Support Level | $104.38 | $73.09 |
| Resistance Level | $110.27 | $78.77 |
| Average True Range (ATR) | 2.69 | 3.15 |
| MACD | 0.59 | -1.02 |
| Stochastic Oscillator | 88.99 | 18.45 |
Lear Corp designs, develops, and manufactures automotive seating and electrical systems and components. The company has two reporting segments Seating and E-Systems. Seating components include frames and mechanisms, covers (leather and woven fabric), seat heating and cooling, foam, and headrests. Automotive electrical distribution and connection systems and electronic systems include wiring harnesses, terminals and connectors, on-board battery chargers, high-voltage battery management systems. The company earns majority of its revenue from the seating segment.
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The Company views its operations and manages its business in one operating segment: life science.